Axogen Q3 Revenue Rises 26%, 2026 Target Set at $290 Million

Axogen Corporation (Nasdaq: AXGN) reported a 26.2% increase in third-quarter revenue and higher adjusted profitability as growth in breast procedures and continued adoption across its nerve-repair markets supported sales. The company expects full-year 2026 revenue of at least $290 million, representing growth of at least 29%, while targeting positive free cash flow and a gross margin of at least 73%.

Revenue for the quarter ended September 30 reached $75.8 million, up from $60.1 million a year earlier. GAAP net income rose to $2.3 million, or $0.04 per diluted share, from $708,000, or $0.01 per share, in the prior-year period.

Adjusted net income was $13.1 million, or $0.21 per diluted share, compared with $6.1 million, or $0.12 per share, a year earlier. The adjusted results exclude noncash stock-based compensation and BioCircuit transaction and integration costs. Adjusted EBITDA increased to $13.4 million from $9.2 million, while the adjusted EBITDA margin expanded to 17.7% from 15.4%.

Third-quarter gross margin was 74.8%, down from 76.6% in the same period of 2025. Total costs and expenses increased 26.5% to $55.8 million, broadly matching the pace of revenue growth. Sales and marketing expenses rose to $30.4 million from $25.7 million, research and development spending increased to $9.0 million from $7.6 million, and general and administrative expenses climbed to $16.5 million from $10.8 million.

For the first nine months of 2026, revenue totaled $207.0 million, compared with $165.3 million a year earlier. Axogen recorded a GAAP net loss of $18.8 million, or $0.35 per share, reflecting items that included a $16.8 million loss on the extinguishment of debt. Adjusted net income was $24.5 million, or $0.41 per diluted share, and adjusted EBITDA reached $27.5 million, with a margin of 13.3%.

Free cash flow for the nine-month period was $18.9 million, compared with negative $5.9 million in the prior-year period. Axogen ended the quarter with $350.1 million in cash, cash equivalents, restricted cash and investments and said it had no debt obligations.

Breast Growth and Commercial Expansion

Axogen said its breast business grew by more than 50% year over year, supported by market-development activity, sales-force expansion and coverage. The extremities business maintained steady growth, while oral and maxillofacial and head-and-neck applications continued to gain adoption through additional surgeon activation and execution at designated high-potential accounts.

The company had 31 breast sales representatives and three regional directors during the quarter, along with 132 extremities representatives and 15 regional directors. Those staffing levels were around its year-end objectives of approximately 30 breast representatives and 130 extremities representatives.

High-potential accounts generated 55% of Axogen’s year-to-date revenue growth, with productivity at those accounts rising 22% from a year earlier. The company reported more than 690 such accounts and said it added over 280 active surgeons during the first nine months. It also conducted 12 education programs, training 208 surgeons and 108 surgeon pairs.

Prostate Development and BioCircuit Acquisition

Axogen reported more than 220 prostate procedures across 15 active clinical-experience sites. The company plans to present detailed clinical outcomes and market research related to the prostate opportunity on November 9, 2026. Its prostate team included three clinical-development managers and one director.

The company also acquired BioCircuit Technologies, adding NerveTape, a coaptation aid designed to eliminate the need for microsuturing. Axogen said the technology complements its Avance product and can also be used in direct nerve repair.

Commercial payer coverage for Avance represented approximately 96% of covered lives in the U.S. Axogen also said the MATCH comparison of Avance and autograft in mixed and motor nerves had been published, the first patient had enrolled in the Nerve-RESTORE study, and the EMBRACE study remained on track for its first site initiation by year-end.

2026 Outlook and Risks

In addition to its target of at least $290 million in total revenue, Axogen expects organic revenue of at least $283 million, or growth of at least 26%, for 2026. Management’s stated priorities include disciplined profitable growth, margin improvement, commercial expansion and further development of elective, planned and prostate procedures.

The outlook remains subject to risks including supply-chain conditions, inflation, hospital staffing constraints, clinical enrollment and outcomes, regulatory processes, surgeon and product adoption, and broader geopolitical and macroeconomic conditions. The anticipated benefits of the BioCircuit acquisition and the company’s prostate expansion also depend on future commercial, clinical and operational execution.